A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis

Clinical Neuropharmacology

Volumn 19, Issue 6, 1996, Pages 497-506

  Pantoni, Leonardo ^a   Carosi, Mauro ^b   Amigoni, Silva ^b   Mascalchi, Mario ^c   Inzitari, Domenico ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Bayer SpA Italy   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Clinical trial; Dementia; Leukoaraiosis; Nimodipine; Vascular dementia

Indexed keywords

NIMODIPINE;

ADULT; APATHY; ARTICLE; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DETERIORATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOARAIOSIS; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL;

EID: 0029821586     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619060-00003     Document Type: Article

References (62)

1. Jorm AF. Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci 1991;240:218-22.
2. Meyer JS, Judd BW, Tawakina T, Rogers RL, Mortel KF. Improved cognition after control of risk factors for multi-infarct dementia. JAMA 1986;256:2203-9.
3. Wade JPH. Multi-infarct dementia: prevention and treatment. Alzheimer Dis Assoc Disord 1991; 5:144-8.
4. Martin R, Alberdi M, Matías-Guiu. Treatment of vascular dementia. In: Culebras A. Matías-Guiu J, Román GC, eds. New concepts in vascular dementia. Barcelona: Prous Science, 1993:123-30.
5. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lofti J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989;37:549-55.
6. Loeb C. Vascular dementia. Dementia 1990;1:175-84.
7. Garcia JH, Brown GG. Vascular dementia: neuropathological alterations and metabolic brain changes. J Neurol Sci 1992;109:121-31.
8. Fisher CM. Binswanger's encephalopathy: a review. J Neurol 1989;236:65-79.
9. Olszewski J. Subcortical arteriosclerotic encephalopathy. World Neurol 1962;3:359-75.
10. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol 1987;44:21-3.
11. Breteler MMB, van Amerongen NM, van Swieten JC, et al. Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study. Stroke 1994;25:1109-15.
12. Meyer JS, Kawamura J, Terayama Y. White matter lesions in the elderly. J Neurol Sci 1994;110: 1-7.
13. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986;19:253-62.
14. Erkinjuntti T, Gao F, Lee DH, Eliasziw M, Merskey H, Hachinski VC. Lack of difference in brain hyperintensities between patients with early Alzheimer's disease and control subjects. Arch Neurol 1994;51:260-8.
15. Inzitari D, Marinoni M, Ginanneschi A, et al. Pathophysiology of leucoaraiosis. In: Culebras A. Matías Guiu J, Román G, eds. New concepts in vascular dementia. Barcelona: Prous Science, 1993:103-13.
16. Inzitari D, Di Carlo AS, Mascalchi M, Pracucci G, Amaducci L. The cardiovascular outcome of patients with motor impairment and extensive leuko-araiosis. Arch Neurol 1995;52:687-91.
17. Menazzi D, Montenegro R, Castro JM. Nimodipine in the treatment of chronic cerebrovascular insufficiency. In: Betz E, Deck K, Hoffmeister F, eds. Nimopidine: pharmacological and clinical properties. Stuttgart: Schattauer FK, 1985:334-44.
18. Tobares N, Pedromingo A, Bigorra J. Nimodipine treatment improves cognitive function in vascular dementia. In: Bergener M, Reisberg B, eds. Diagnosis and treatment of senile dementia. Berlin: Springer-Verlag, 1989:360-5.
19. Auer LM, Oberbauer RM, Schalk HV. Human pial vascular reaction to intravenous nimodipine infusion during EC-IC bypass surgery. Stroke 1983;14:210-21.
20. Fieschi C, Argentino C, Toni D, Pozzilli C. Calcium antagonists in ischemic stroke. J Cardiovasc Pharmacol 1988;12(suppl 6):S83-5.
21. Jansen I, Tfelt-Hansen P, Edvinsson L. Comparison of the calcium entry blockers nimodipine and flunarizine on human cerebral and temporal arteries: role in cerebrovascular disorders. Eur J Clin Pharmacol 1991;40:7-15.
22. Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in cerebrovascular disease. Drugs 1989;37:669-99.
23. Takayasu M, Basset JE, Dacey RG. Effects of calcium antagonists on intracerebral penetrating arterioles in rats. J Neurosurg 1988;69:104-9.
24. Dorsch NWC, Branston NM, Harris RJ, Bentivoglio P, Symon L. An experimental study of the effect of nimodipine in primate subarachnoid hemorrhage. Acta Neurochir 1989;99:65-75.
25. Greenberg JH, Uematsu D, Araki N, Hickey WF, Reivich M. Cytosolic free calcium during focal cerebral ischemia and the effects of nimodipine on calcium and histologic damage. Stroke 1990; 21(suppl IV):IV72-7.
26. De Jong GI, Traber J, Luiten PGM. Formation of cerebrovascular anomalies in the ageing rats is delayed by chronic nimodipine application. Mech Ageing Dev 1992;64:255-72.
27. Itil TM, Itil KZ. The comparative CNS: pharmacology of nimodipine in humans. In: Betz E, Deck K, Hoffmeister F, eds. Nimodipine: pharmacological and clinical properties. Stuttgart: Schattauer FK, 1985:185-202.
28. Scriabine A, Schuurman T, Traber J. Pharmacological basis for the use of nimodipine in central nervous system disorders. FASEB J 1989;3:1799-806.
29. Welsch M, Nuglisch J, Krieglstein J. Neuroprotective effect of nimodipine is not mediated by increased cerebral blood flow after transient forebrain ischemia in rats. Stroke 1990;21(suppl IV):IV105-7.
30. Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery 1988;23: 154-7.
31. Mee E, Dorrance D, Lowe D, Neil-Dwyer G. Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage. Neurosurgery 1988;22:484-91.
32. Ohman J, Heiskanen O. Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 1988;69:683-6.
33. Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988;68:505-17.
34. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British Aneurysm Nimodipine Trial. Br Med J 1989; 298:636-42.
35. Ban TA, Morey L, Aguglia E, et al. Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:525-51.
36. Fischhof PK, Wagner G, Littschauer L, et al. Therapeutic results with nimodipine in primary degenerative dementia and multi-infarct dementia. In: Bergener M, Reisberg B, eds. Diagnosis and treatment of senile dementia. Berlin: Springer-Verlag, 1989:350-9.
37. Kanowski S, Fischhof P, Hiersemenzel R, Roehmel J, Kern U. Therapeutic efficacy of nootropic drugs. A discussion of clinical phase III studies with nimodipine as a model. In: Bergener M, Reisberg B, eds. Diagnosis and treatment of senile dementia. Berlin: Springer-Verlag, 1989:339-49.
38. Schmage N, Boehme K, Dicka J, Schmilz H. Nimodipine for psychogeriatric use: methods, strategies and considerations based on experience with clinical trials. In: Bergener M, Reisberg B, eds. Diagnosis and treatment of senile dementia. Berlin: Springer-Verlag, 1989:374-81.
39. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (BAY-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990;27:1133-42.
40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed rev. Washington, D.C.: American Psychiatric Association, 1987.
41. Reisberg B, Ferris SH, De Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
42. Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment on geriatric populations: Sandoz Clinical Assessment Geriatric (SCAG). J Am Geriatr Soc 1974;22:107-13.
43. Hachinski VC, Iliff LD, Zilkha E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32: 632-7.
44. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-44.
45. Inzitari D, Diaz F, Fox A, et al. Vascular risk factors and leuko-araiosis. Arch Neurol 1987;44: 42-7.
46. Akhtar AJ, Broe GA, Crombie A, McLean WMR, Andrews GR, Caird FI. Disability and dependence in the elderly at home. Age Ageing 1973;2:102-11.
47. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114: 797-811.
48. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
49. Randt CT, Brown ER, Osborne DP Jr. A memory test for longitudinal measurement of mild to moderate deficits. Clin Neuropsychol 1980;4:184-94.
50. Wechsler D. A standardized memory scale for clinical use. J Psychol 1945;19:87-95.
51. De Renzi E, Faglioni P, Ruggini C. Prove di memoria verbale di impiego clinico per la diagnosi di amnesia. Arch Psicol Neurol Psichiat 1977;3:303-18.
52. Milner B. Interhemispheric differences in the localization of psychological process in man. Br Med Bull 1971;27:272-6.
53. Isaacs B, Kennie AT. The set test as an aid to the detection of dementia in old people. Br J Psychiatry 1973;123:467-70.
54. De Renzi E, Vignolo LA. The token test: a sensitive test to detect receptive disturbances in aphasics. Brain 1962;85:665-72.
55. Pattie AH, Gilleard CJ. A brief psychogeriatric assessment schedule. Br J Psychiatry 1975;127: 489-93.
56. Arrigoni G, De Renzi E. Constructional apraxia and hemispheric locus of lesions. Cortex 1964; 1:170-8.
57. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: Wiley, 1980.
58. Caplan LR, Schoene WC. Clinical features of subcortical arteriosclerotic encephalopathy (Binswanger disease). Neurology 1978;28:1206-15.
59. Montenegro R, Cornide E, Castro JM. Nimodipine in the treatment of involutional depressive syndrome. In: Betz E, Deck K. Hoffmeister F, eds. Nimodipine: pharmacological and clinical properties. Stuttgart: Schattauer FK, 1985:345-58.
60. Räihä I, Tarvonen S, Kurki T, Rajala T, Sourander L. Relationship between vascular factors and white matter low attenuation of the brain. Acta Neurol Scand 1993;87:286-9.
61. Ringelstein EB, Mauckner A, Schneider R, et al. Effects of enzymatic blood defibrination in subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry 1988;51:1051-7.
62. Hachinski V. Binswanger's disease: neither Binswanger's nor a disease. J Neurol Sci 1991;103:1.